ACTEMRA®1 (tocilizumab) by Biogen, shows great potential in treatment of severe Rheumatoid Arthritis

Biogen Inc. announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 (IL-6) receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA®1 (tocilizumab).

Clinical Trials: NCT03830203